BRPI0810800A2 - Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles. - Google Patents

Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles.

Info

Publication number
BRPI0810800A2
BRPI0810800A2 BRPI0810800-5A2A BRPI0810800A BRPI0810800A2 BR PI0810800 A2 BRPI0810800 A2 BR PI0810800A2 BR PI0810800 A BRPI0810800 A BR PI0810800A BR PI0810800 A2 BRPI0810800 A2 BR PI0810800A2
Authority
BR
Brazil
Prior art keywords
quinazolin
dioxy
thiophen
methylamino
dihydro
Prior art date
Application number
BRPI0810800-5A2A
Other languages
English (en)
Inventor
Emma Sharp
Louisa Jane Quegan
Anjali Pandey
Juan Wang
Matthew Nieder
Wolin Huang
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of BRPI0810800A2 publication Critical patent/BRPI0810800A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0810800-5A2A 2007-05-02 2008-05-02 Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles. BRPI0810800A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92732807P 2007-05-02 2007-05-02
PCT/US2008/062584 WO2008137809A2 (en) 2007-05-02 2008-05-02 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BRPI0810800A2 true BRPI0810800A2 (pt) 2014-10-29

Family

ID=39651344

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810800-5A2A BRPI0810800A2 (pt) 2007-05-02 2008-05-02 Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles.

Country Status (18)

Country Link
US (1) US20090042916A1 (pt)
EP (1) EP2076510A2 (pt)
JP (1) JP2010526105A (pt)
KR (1) KR20100020455A (pt)
CN (1) CN101720324A (pt)
AU (1) AU2008247457A1 (pt)
BR (1) BRPI0810800A2 (pt)
CA (1) CA2686221A1 (pt)
CO (1) CO6241155A2 (pt)
EA (1) EA200901474A1 (pt)
EC (1) ECSP099779A (pt)
GT (1) GT200900282A (pt)
IL (1) IL201829A0 (pt)
MA (1) MA31397B1 (pt)
MX (1) MX2009011836A (pt)
TN (1) TN2009000452A1 (pt)
WO (1) WO2008137809A2 (pt)
ZA (1) ZA200907493B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
WO2011006169A1 (en) 2009-07-10 2011-01-13 Portola Pharmaceuticals, Inc. Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
JP2013544271A (ja) * 2010-12-03 2013-12-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法
CN106777526B (zh) * 2016-11-25 2020-05-01 江苏大学 基于遗传算法的高温高压离心式叶轮多学科优化方法
WO2019126557A1 (en) 2017-12-22 2019-06-27 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use
US10933096B2 (en) 2017-12-22 2021-03-02 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4720450A (en) * 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
DE60144284D1 (de) * 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US20040242658A1 (en) * 2003-01-08 2004-12-02 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
PL1668002T3 (pl) * 2003-10-03 2010-02-26 Portola Pharm Inc 2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika
CA2627719C (en) * 2005-11-03 2016-07-12 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20090048216A1 (en) * 2007-05-02 2009-02-19 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Also Published As

Publication number Publication date
JP2010526105A (ja) 2010-07-29
TN2009000452A1 (en) 2011-03-31
CO6241155A2 (es) 2011-01-20
EP2076510A2 (en) 2009-07-08
ZA200907493B (en) 2010-07-28
MX2009011836A (es) 2010-05-20
CN101720324A (zh) 2010-06-02
GT200900282A (es) 2010-05-21
EA200901474A1 (ru) 2010-04-30
CA2686221A1 (en) 2008-11-13
MA31397B1 (fr) 2010-05-03
IL201829A0 (en) 2010-06-16
AU2008247457A1 (en) 2008-11-13
ECSP099779A (es) 2010-01-29
US20090042916A1 (en) 2009-02-12
WO2008137809A3 (en) 2009-01-22
WO2008137809A2 (en) 2008-11-13
KR20100020455A (ko) 2010-02-22

Similar Documents

Publication Publication Date Title
BRPI1012198A8 (pt) sais de dissacarina, ácido difumárico, ácido di-1-hidróxi-2-naftoico e ácido mono-benzoico de 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il)metil) fenil) acetato de 4-(dimetilamino)butila
FR2919196B1 (fr) Descendeur autobloquant a poignee debrayable.
BRPI0923409A2 (pt) cabeça de escova de dentes, e, escova de dentes.
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
BRPI0920428A2 (pt) inalador.
PT3112358T (pt) Sais de xantílio 3,6-dissubstituídos
CL2007002783S1 (es) Inhalador multidosis.
BRPI0815773A2 (pt) composto, e, medicamento.
BRPI0913112A2 (pt) fluxímetro, e, método.
BRPI0922466A2 (pt) sais
BRPI0814736A2 (pt) inalador.
BRPI0914584A2 (pt) Método, e, composição herbicida.
EP1951254A4 (en) [(2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL] -5-CHLORO-THIOPHENE-2-YL-SULFONYLUREES [4- (6-HALO-7-SUBSTITUTEES)] AND ASSOCIATED FORMS AND METHODS
FR2914820B1 (fr) Boucle auriculaire renforcee.
BRPI0921649A2 (pt) sais de [4-(6-flúor-7-metil-amino-2-4-dioxo-1,4-dioxo-1,4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureia, formas e métodos relacionados a eles
BRPI1009236A2 (pt) Aperfeiçoamentos em, e referentes a, composições biocidas.
FR2927552B1 (fr) Pulverisateur, notamment a usage medical
BRPI0807992A2 (pt) Sais de adição do ácido, hidratos e polimorfos de etilamida do ácido 5-(2-4-di-hidróxi-5-isopropil-fenil)-4-(4-morfolin-4-ilme til-fenil) isoxazol-3-carboxílico e formulações compreendendo essas formas.
IL201829A0 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
BRPI0918035A2 (pt) inserto, e, cortador lateral.
IT1397968B1 (it) Composizione pesticida acquosa.
BRPI0917699A2 (pt) Composição herbicida aquosa, e, composição de matéria
BRPI0815716A2 (pt) Decapagem secundária econômica.
BRPI0922668A2 (pt) processo para a fabricação de sais sólidos, sais sólidos, e, uso de sais sólidos
FR2919195B1 (fr) Descendeur autobloquant a poignee debrayable.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]